glp-1 drug news Risks of Ozempic, other drugs are at center of sweeping lawsuit that kicked off in Philadelphia Poll: 1 in 8 Adults

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

In 2025 we saw label expansions for semaglutide and tirzepatide, underscoring a trend toward whole-body health

Explore the implications of proposed changes to GLP-1 medication coverage and their impact on Medicare and Medicaid health plans

Buy Retatrutide Canada (120 mg) for research involving triple-agonist metabolic pathways, energy regulation, and adipose signaling

Allulose is a rare sugar that may modestly support GLP-1 secretion through gut hormone pathways, but dietary changes alone rarely match the effect of prescription GLP-1 therapy

Within professional research environments, Retatrutide is frequently examined for its role in